コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 gulated in dilated cardiomyopathy but not in hypertrophic cardiomyopathy.
2 er phenotypes, including 1,078 patients with hypertrophic cardiomyopathy.
3 ice developed a cardiac phenotype similar to hypertrophic cardiomyopathy.
4 tonia, optic atrophy, axonal neuropathy, and hypertrophic cardiomyopathy.
5 f cardiac disease, such as arrhythmogenic or hypertrophic cardiomyopathy.
6 MI), patients undergoing septal ablation for hypertrophic cardiomyopathy.
7 eta-adrenergic signaling, heart failure, and hypertrophic cardiomyopathy.
8 f MF in 30 transplanted hearts of end-stage, hypertrophic cardiomyopathy.
9 s support a cumulative variant hypothesis in hypertrophic cardiomyopathy.
10 lcohol septal ablation (ASA) in patient with hypertrophic cardiomyopathy.
11 Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy.
12 red with suspicion of genetically determined hypertrophic cardiomyopathy.
13 On autopsy, a patient is found to have hypertrophic cardiomyopathy.
14 ides prognostic information in patients with hypertrophic cardiomyopathy.
15 ar hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy.
16 ions, like mice with similar mutations, have hypertrophic cardiomyopathy.
17 med in 558 consecutive proband patients with hypertrophic cardiomyopathy.
18 ts had a structurally normal heart and 3 had hypertrophic cardiomyopathy.
19 providing a preclinical marker of disease in hypertrophic cardiomyopathy.
20 nted with lactic acidosis and nine developed hypertrophic cardiomyopathy.
21 ondrial disease patient who died of neonatal hypertrophic cardiomyopathy.
22 outcomes in a large cohort of patients with hypertrophic cardiomyopathy.
23 n genes coding for sarcomeric proteins cause hypertrophic cardiomyopathy.
24 ely to be a highly penetrant variant causing hypertrophic cardiomyopathy.
25 3 criteria identified 98.1% of athletes with hypertrophic cardiomyopathy.
26 lied to 4297 WAs and 103 young athletes with hypertrophic cardiomyopathy.
27 peptide (BNP) and survival in patients with hypertrophic cardiomyopathy.
28 s associated with worse clinical outcomes in hypertrophic cardiomyopathy.
29 rmalities and tissue injury in patients with hypertrophic cardiomyopathy.
30 ere mutation carriers at risk for developing hypertrophic cardiomyopathy.
31 nd tissue injury are common in patients with hypertrophic cardiomyopathy.
32 between DE on CMR and myocardial ischemia in hypertrophic cardiomyopathy.
33 t of routine evaluation of all patients with hypertrophic cardiomyopathy.
34 anxiety-like behavior in an animal model of hypertrophic cardiomyopathy.
35 in successfully prevented the development of hypertrophic cardiomyopathy.
36 bstitution in Sco1, which in humans causes a hypertrophic cardiomyopathy.
37 ostic value of GLS and LAVI in patients with hypertrophic cardiomyopathy.
38 nical management and genetic architecture of hypertrophic cardiomyopathy.
39 duced MEE at the early and advanced stage of hypertrophic cardiomyopathy.
40 nt of Fabry disease mimicking nonobstructive hypertrophic cardiomyopathy.
41 ng improves exercise capacity in adults with hypertrophic cardiomyopathy.
42 achycardia, congenital long QT syndrome, and hypertrophic cardiomyopathy.
43 ficiency causes Danon's disease, an X-linked hypertrophic cardiomyopathy.
47 ears; P<0.001), and have a family history of hypertrophic cardiomyopathy (53% versus 20%; P<0.001), a
48 n), 67 patients with a clinical diagnosis of hypertrophic cardiomyopathy (53+/-15 years, 76% men; 31
49 pertension (-4); positive family history for hypertrophic cardiomyopathy (6); morphology category (5)
50 diography was performed in 427 patients with hypertrophic cardiomyopathy (66% men, age 52+/-15 years)
51 e was established in 44.5% of athletes, with hypertrophic cardiomyopathy (81%) the most common pathol
53 ients undergoing septal alcohol ablation for hypertrophic cardiomyopathy, a human model of planned my
57 fficiency represents a target for therapy in hypertrophic cardiomyopathy although therapeutic benefit
59 ry hypertension in patients with obstructive hypertrophic cardiomyopathy and advanced heart failure.
60 vein (PV) antrum isolation in patients with hypertrophic cardiomyopathy and atrial fibrillation (AF)
62 ducible hypoperfusion is a common finding in hypertrophic cardiomyopathy and is typically identified
64 ciated with adverse outcome in patients with hypertrophic cardiomyopathy and may help to optimize ris
65 tions reflect the complex pathophysiology of hypertrophic cardiomyopathy and may provide clues for th
66 tive athletes, two deaths were attributed to hypertrophic cardiomyopathy and none to arrhythmogenic r
67 sitivity of the myofilaments is increased in hypertrophic cardiomyopathy and other heart diseases and
68 d RagB (RagA/B) in cardiomyocytes results in hypertrophic cardiomyopathy and phenocopies lysosomal st
69 variety of clinical manifestations including hypertrophic cardiomyopathy and renal insufficiency.
70 R21C (cTnI-R21C) mutation has been linked to hypertrophic cardiomyopathy and renders cTnI incapable o
71 e and are told that they are not at risk for hypertrophic cardiomyopathy and sudden cardiac death, an
72 at have previously been considered causal in hypertrophic cardiomyopathy and that are overrepresented
73 conversions associated with fatal infantile hypertrophic cardiomyopathy and the neurological disorde
74 ified a dose-dependent induction of dilated, hypertrophic cardiomyopathy, and arrhythmia inducibility
75 lic dysfunction, predisposing gene variants, hypertrophic cardiomyopathy, and congenital heart diseas
76 iles for healthy subjects, long QT syndrome, hypertrophic cardiomyopathy, and dilated cardiomyopathy
77 henotypes were verified in long QT syndrome, hypertrophic cardiomyopathy, and dilated cardiomyopathy
78 inergic polymorphic ventricular tachycardia, hypertrophic cardiomyopathy, and other hereditary cardia
79 nted in childhood with failure to thrive and hypertrophic cardiomyopathy, and the other was an adult
80 vity are consistent with the hypothesis that hypertrophic cardiomyopathies are hypersensitive to Ca(2
83 gests that double mutations in patients with hypertrophic cardiomyopathy are not rare and are associa
86 nder fasting conditions.Sirt5KO mice develop hypertrophic cardiomyopathy, as evident from the increas
87 importance of this finding in patients with hypertrophic cardiomyopathy, as well as the long-term sa
90 8V proband diagnosed with severe obstructive hypertrophic cardiomyopathy at 34 years of age exhibited
91 children who were diagnosed with idiopathic hypertrophic cardiomyopathy at age 1 year or older, with
93 sidase A gene variants are misinterpreted as hypertrophic cardiomyopathy because of the lack of extra
95 n thin-filament proteins have been linked to hypertrophic cardiomyopathy, but it has never been demon
96 wn to halt or reverse disease progression in hypertrophic cardiomyopathy, but the results of several
97 4R has previously been linked to dilated and hypertrophic cardiomyopathy, but was also found in healt
98 ure of cardiomyopathies, with an emphasis on hypertrophic cardiomyopathy caused by sarcomeric mutatio
99 -helix bundle that are associated with human hypertrophic cardiomyopathy caused either loss-of-functi
100 is, we first investigated the impact of five hypertrophic cardiomyopathy-causing (N1327K, E1356K, R13
101 ce in SHaRe most frequently occurred because hypertrophic cardiomyopathy centers had access to differ
102 Discordance in variant classification among hypertrophic cardiomyopathy centers is largely attributa
103 ment may be achieved by: 1) confining ASA to hypertrophic cardiomyopathy centers of excellence with h
105 ate tool to predict a positive genotype in a hypertrophic cardiomyopathy cohort at a tertiary referra
106 ted to outflow obstruction (7% of the entire hypertrophic cardiomyopathy cohort) followed up for 6.1+
107 in genes associated with the pathogenesis of hypertrophic cardiomyopathy, dilated cardiomyopathy, and
108 iotensin II receptor blockers in preclinical hypertrophic cardiomyopathy-eg, in genotype-positive but
109 heart transplantation (HT) in patients with hypertrophic cardiomyopathy evaluated at 2 Italian refer
110 d >3 times and accounted for 78 of 185 (42%) hypertrophic cardiomyopathy families with a causal varia
112 Moreover, MR is key in differentiating HCM hypertrophic cardiomyopathy from "phenocopies"-that is,
114 ic cardiomyopathy who had undergone targeted hypertrophic cardiomyopathy genetic testing (either mult
116 more than a decade, risk stratification for hypertrophic cardiomyopathy has been enhanced by targete
119 t of drug-refractory symptoms of obstructive hypertrophic cardiomyopathy has long been debated and is
121 alcohol septal ablation (ASA) in obstructive hypertrophic cardiomyopathy have been limited to small,
126 in clinical practice, in particular, between hypertrophic cardiomyopathy (HCM) and increased LV wall
128 verely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM) and mild septal hypert
129 pathogenic mutations in the TNT1 region, six hypertrophic cardiomyopathy (HCM) and two dilated cardio
131 Heterozygous mutations in sarcomere genes in hypertrophic cardiomyopathy (HCM) are proposed to exert
132 tain clinical and genetic characteristics of hypertrophic cardiomyopathy (HCM) at the population leve
133 tein C) founder mutations account for 35% of hypertrophic cardiomyopathy (HCM) cases in the Netherlan
134 terations in autophagy have been reported in hypertrophic cardiomyopathy (HCM) caused by Danon diseas
135 rizes the stereotypic phenotype proposed for hypertrophic cardiomyopathy (HCM) caused by thin-filamen
137 eft ventricular obstruction in patients with hypertrophic cardiomyopathy (HCM) during exercise echoca
139 graphic data for automated discrimination of hypertrophic cardiomyopathy (HCM) from physiological hyp
160 mplete penetrance and variable expression of hypertrophic cardiomyopathy (HCM) is well appreciated.
161 specific clinical red flags in patients with hypertrophic cardiomyopathy (HCM) older than 25 years.
162 ibuted to structural heart diseases, such as hypertrophic cardiomyopathy (HCM) or cardiac channelopat
163 hich they represent prephenotypic markers of hypertrophic cardiomyopathy (HCM) or incidental structur
164 A previously under-recognized subset of hypertrophic cardiomyopathy (HCM) patients with left ven
165 ere differentially expressed in the blood of hypertrophic cardiomyopathy (HCM) patients, and whether
167 of a phosphorylation-mediated reversal of a hypertrophic cardiomyopathy (HCM) phenotype is novel.
168 h genetic mutations that are associated with hypertrophic cardiomyopathy (HCM) remains challenging.
170 European Society of Cardiology guidelines of hypertrophic cardiomyopathy (HCM) use a new clinical ris
171 with severe heart failure due to obstructive hypertrophic cardiomyopathy (HCM) who are at unacceptabl
173 5% for dilated cardiomyopathy (DCM), 6% for hypertrophic cardiomyopathy (HCM), 12% for restrictive c
174 utation cTnI-R145G, which is associated with hypertrophic cardiomyopathy (HCM), a disease associated
175 c myosin heavy chain gene (MYH7) can lead to hypertrophic cardiomyopathy (HCM), a heritable disease c
177 ted cardiomyopathy (NIDCM), 20 patients with hypertrophic cardiomyopathy (HCM), and 20 control health
178 for treatment of long QT-3 syndrome (LQT-3), hypertrophic cardiomyopathy (HCM), and ventricular tachy
179 ng vasodilator stress in patients with overt hypertrophic cardiomyopathy (HCM), as well as in HCM mut
182 enetically heterogeneous conditions, such as hypertrophic cardiomyopathy (HCM), in which a considerab
183 AF), the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM), is capable of produci
184 the time of greatest risk for patients with hypertrophic cardiomyopathy (HCM), largely because of th
185 omeric mutation, which is exhibited in human hypertrophic cardiomyopathy (HCM), to investigate the in
186 ns, such as dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM), which are often due t
198 this case the two major clinical phenotypes (hypertrophic cardiomyopathy, HCM and dilated cardiomyopa
199 imaging in relation to the complexity of HCM hypertrophic cardiomyopathy , highlighting its role in c
200 Chronic or low-dose exposure may lead to hypertrophic cardiomyopathy; however, only acute exposur
202 post-mortem diagnosis; the most common were hypertrophic cardiomyopathy in 21 and congenital coronar
203 lts, clinicians routinely assess the risk of hypertrophic cardiomyopathy in a patient's relatives and
204 with abnormal ECG and with 1 case of apical hypertrophic cardiomyopathy in heterozygous females.
206 rn pathological and clinical descriptions of hypertrophic cardiomyopathy in the 1950s, which focused
207 e of multiple rare variants in patients with hypertrophic cardiomyopathy in the setting of comprehens
208 -month follow-up, 2 subjects developed overt hypertrophic cardiomyopathy, including 1 with mild LVH b
210 atients followed at the Tufts Medical Center Hypertrophic Cardiomyopathy Institute for 4.8+/-3.4 year
211 used for other indications in patients with hypertrophic cardiomyopathy, irrespective of obstructive
217 g exercise recommendations for patients with hypertrophic cardiomyopathy is challenging because of co
219 tricular tachycardia (NSVT) in patients with hypertrophic cardiomyopathy is incompletely resolved.
221 for additional genes that are implicated in hypertrophic cardiomyopathy is initiated on an affected
224 The most common single genetic cause of hypertrophic cardiomyopathy is the recurrent MYBPC3 (myo
226 cardial strain are reported in patients with hypertrophic cardiomyopathy, ischemic heart disease, dia
227 n binding protein-C or titin, cause familial hypertrophic cardiomyopathies, it is important to determ
228 of myocardial perfusion; characterization of hypertrophic cardiomyopathy, left ventricular noncompact
229 ercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) trial, the lar
230 KI mice, whereas A399S-PKI mice expressing a hypertrophic cardiomyopathy-linked JPH2 mutation not ass
231 sis light chain [AL] type), 40 patients with hypertrophic cardiomyopathy matched for demographics and
232 ND One-hundred and ninety-five patients with hypertrophic cardiomyopathy (median age, 52.8+/-15.1 yea
235 is preliminary study involving patients with hypertrophic cardiomyopathy, moderate-intensity exercise
237 ular cardiomyopathy (n = 111), DCM (n = 95), hypertrophic cardiomyopathy (n = 40) and peripartum card
238 2), occult myocardial infarction (n=13), and hypertrophic cardiomyopathy (n=9) were most frequent.
239 ng abnormality and thus shares features with hypertrophic cardiomyopathies observed in the congenital
240 diac death (SCD) in athletes is debated with hypertrophic cardiomyopathy often reported as the most c
241 e underlying sarcomere hypercontractility of hypertrophic cardiomyopathy, one of the most prevalent h
245 iameter, volume, and strain to risk stratify hypertrophic cardiomyopathy patients for new-onset atria
246 preferred methods to relieve obstruction in hypertrophic cardiomyopathy patients still symptomatic a
250 dictors of long-term outcomes of symptomatic hypertrophic cardiomyopathy patients undergoing surgical
253 onary hypertension was common in obstructive hypertrophic cardiomyopathy patients with advanced heart
254 of measured cardiopulmonary hemodynamics in hypertrophic cardiomyopathy patients with heart failure,
255 ith similar EF in 20 control subjects and 20 hypertrophic cardiomyopathy patients with increased wall
256 op of LA diameter to predict new-onset AF in hypertrophic cardiomyopathy patients with LA diameter <4
259 e diagnosis and prognostic assessment of HCM hypertrophic cardiomyopathy patients, as well as screeni
262 an with detailed characterization of the HCM hypertrophic cardiomyopathy phenotype and assessment of
265 g was performed on 358 consecutive genotyped hypertrophic cardiomyopathy probands at 5 tertiary hyper
267 Icelandic patients clinically diagnosed with hypertrophic cardiomyopathy resulted in identification o
268 itral regurgitation, prior valvular surgery, hypertrophic cardiomyopathy, rheumatic valvular disease,
271 one of several preclinical abnormalities in hypertrophic cardiomyopathy sarcomere gene mutation carr
272 actors for poor outcomes varied according to hypertrophic cardiomyopathy subgroup, but they generally
274 rmine whether TNNC1 can be categorized as an hypertrophic cardiomyopathy susceptibility gene, such th
275 markedly lower among centers specialized in hypertrophic cardiomyopathy than among clinical laborato
277 ation (ASA) for the treatment of obstructive hypertrophic cardiomyopathy, the arrhythmogenicity of th
278 l fibrosis (MF) has clinical implications in hypertrophic cardiomyopathy, the extent, type, and distr
280 magnetic resonance parameters in subclinical hypertrophic cardiomyopathy to determine their strength
281 ercise testing is performed in patients with hypertrophic cardiomyopathy to evaluate blood pressure r
282 -15 years, range 16-86 years; 67% male) with hypertrophic cardiomyopathy underwent cardiopulmonary ex
284 thogenic sarcomere mutation in patients with hypertrophic cardiomyopathy was associated with an incre
285 d clinical trial involving 136 patients with hypertrophic cardiomyopathy was conducted between April
288 l hypertrophy, traditionally associated with hypertrophic cardiomyopathy, was the commonest pattern o
289 mogenic right ventricular cardiomyopathy and hypertrophic cardiomyopathy were 4.2 to 6.7/100 patient-
290 genic (LP/P; >/=2) variants in patients with hypertrophic cardiomyopathy were described 10 years ago
293 d older) with obstructive or non-obstructive hypertrophic cardiomyopathy were randomly assigned via c
294 ferences between MYH7- and MYBPC3-associated hypertrophic cardiomyopathy when assessed by cardiac mag
296 10 (20%) heterozygous family members showed hypertrophic cardiomyopathy with an atypical distributio
297 were recorded for the 69 children with pure hypertrophic cardiomyopathy with inborn errors of metabo
298 cardiac magnetic resonance imaging revealed hypertrophic cardiomyopathy with left ventricular dysfun
299 mily with 3 males affected by nonobstructive hypertrophic cardiomyopathy with severe left ventricular
300 We studied 699 consecutive patients who have hypertrophic cardiomyopathy with severe symptomatic left
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。